nach oben

Clinical and Translational Oncology

Erschienen in:

21.09.2016 | Review Article

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

verfasst von: A. Lester, R. Rapkins, S. Nixdorf, M. Khasraw, K. McDonald

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.

De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137–46.CrossRefPubMed

Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13(7):411–24.CrossRefPubMed

El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31(19):5526–33.CrossRefPubMedPubMedCentral

Mortusewicz O, Amé J-C, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res. 2007;35(22):7665–75.CrossRefPubMedPubMedCentral

Godon C, Cordelières FP, Biard D, Giocanti N, Mégnin-Chanet F, Hall J, et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 2008;36(13):4454–64.CrossRefPubMedPubMedCentral

Ström CE, Johansson F, Uhlén M, Szigyarto CA-K, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011;39(8):3166–75.CrossRefPubMed

Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly (ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res. 2014;329(1):18–25.CrossRefPubMed

Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Pont LMB, Dirven CM, et al. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. J Transl Med. 2015;13(1):74–83.CrossRefPubMedPubMedCentral

Murai J, Shar-yin NH, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.CrossRefPubMedPubMedCentral

10.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.CrossRefPubMed

11.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–37.CrossRefPubMed

12.

Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta (BBA) Rev Cancer. 2014;1846(1):201–15.CrossRef

13.

Dungey FA, Löser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008;72(4):1188–97.CrossRefPubMed

14.

Russo AL, Kwon H-C, Burgan WE, Carter D, Beam K, Weizheng X, et al. In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016. Clin Cancer Res. 2009;15(2):607–12.CrossRefPubMed

15.

Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Asp Med. 2013;34(6):1217–56.CrossRef

16.

Alexander BM, Ligon KL, Wen PY. Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013;13(5):569–81.CrossRefPubMed

17.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.CrossRefPubMed

18.

Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther. 2006;5(3):564–74.CrossRefPubMed

19.

Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitisation of human glioma cells by combining inhibition of PARP with inhibition of Hsp90. Mol Cancer Ther. 2009;8(8):2243–54.CrossRefPubMedPubMedCentral

20.

Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther. 2010;9(6):1775–87.CrossRefPubMedPubMedCentral

21.

Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008;68(2):605–14.CrossRefPubMed

22.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JCG, Kirkby KJ, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol (Lond Engl). 2013;8:65–75.CrossRef

23.

Venere M, Hamerlik P, Wu Q, Rasmussen R, Song L, Vasanji A, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014;21(2):258–69.CrossRefPubMed

24.

Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol. 2012;2012:10.CrossRef

25.

Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8(2):407–14.CrossRefPubMedPubMedCentral

26.

Majuelos-Melguizo J, Rodríguez MI, López-Jiménez L, Rodríguez-Vargas JM, Martí Martín-Consuegra JM, Serrano-Sáenz S, et al. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget. 2015;6(7):4790–803.CrossRefPubMed

27.

Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105(8):1114–22.CrossRefPubMedPubMedCentral

28.

Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27(41):5443–53.CrossRefPubMed

29.

Chalhoub N, Baker SJ. PTEN and the PI3-Kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–50.CrossRefPubMedPubMedCentral

30.

Baker SJ, McKinnon PJ. Tumour-suppressor function in the nervous system. Nat Rev Cancer. 2004;4(3):184–96.CrossRefPubMed

31.

Hunt CR, Gupta A, Horikoshi N, Pandita TK. Does PTEN loss impair DNA double-strand break repair by homologous recombination? Clin Cancer Res. 2012;18(4):920–2.CrossRefPubMed

32.

Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 1999;18(27):3936–43.CrossRefPubMed

33.

Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem. 2007;2007:21206–12.CrossRef

34.

McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for GBM therapy with temozolomide or PARP inhibitors. Cancer Res. 2010;70(13):5457–64.CrossRefPubMedPubMedCentral

35.

Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther. 2007;14(6):543–9.CrossRefPubMed

36.

Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, et al. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther. 2004;11(4):273–9.CrossRefPubMed

37.

Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res. 2012;18(4):1015–27.CrossRefPubMed

38.

Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;2007:157–70.CrossRef

39.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22.CrossRefPubMedPubMedCentral

40.

Mukherjee A, Karmakar P. Attenuation of PTEN perturbs genomic stability via activation of Akt and down-regulation of Rad51 in human embryonic kidney cells. Mol Carcinog. 2013;52(8):611–8.CrossRefPubMed

41.

Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013;11(2):140–8.CrossRefPubMed

42.

He J, Kang X, Yin Y, Chao KSC, Shen WH. PTEN regulates DNA replication progression and stalled fork recovery. Nat Commun. 2015;2015:6.

43.

Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009;8(14):2198–210.CrossRefPubMed

44.

Ming M, He Y-Y. PTEN in DNA damage repair. Cancer Lett. 2012;319(2):125–9.CrossRefPubMedPubMedCentral

45.

Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14(1):1–10.CrossRef

46.

Gong L, Govan JM, Evans EB, Dai H, Wang E, Lee S-W, et al. Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle. 2015;14(14):2323–32.CrossRefPubMedPubMedCentral

47.

Sun Z, Huang C, He J, Lamb Kristy L, Kang X, Gu T, et al. PTEN C-terminal deletion causes genomic instability and tumor development. Cell Reports. 2014;6(5):844–54.CrossRefPubMedPubMedCentral

48.

Godoy PRDV, Mello SS, Magalhães DAR, Donaires FS, Nicolucci P, Donadi EA, et al. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res, Genet Toxicol Environ Mutagen. 2013;756(1–2):46–55.CrossRef

Titel: Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
verfasst von: A. Lester
R. Rapkins
S. Nixdorf
M. Khasraw
K. McDonald
Publikationsdatum: 21.09.2016
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1547-4

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs

Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients

Thanks to reviewers

M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC

The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward

New clinical trials regulation in Spain: analysis of royal decree 1090/2015

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie